Eagle Pharmaceuticals
EGRX
#10046
Rank
A$21.22 M
Marketcap
$1.64
Share price
0.00%
Change (1 day)
-81.93%
Change (1 year)

P/E ratio for Eagle Pharmaceuticals (EGRX)

P/E ratio as of March 2025 (TTM): 1.12

According to Eagle Pharmaceuticals 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 1.11957. At the end of 2022 the company had a P/E ratio of 10.4.

P/E ratio history for Eagle Pharmaceuticals from 2014 to 2023

PE ratio at the end of each year

Year P/E ratio Change
202210.4-113.43%
2021-77.2-247.44%
202052.3-10.29%
201958.3215.61%
201818.519.01%
201715.53.74%
201615.0-95.27%
2015317-3389.37%
2014-9.63

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
11.6 933.58%๐Ÿ‡บ๐Ÿ‡ธ USA
11.2 900.95%๐Ÿ‡ฌ๐Ÿ‡ง UK
29.2 2,505.80%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
-8.23-835.10%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
22.1 1,873.50%๐Ÿ‡บ๐Ÿ‡ธ USA
148 13,088.37%๐Ÿ‡บ๐Ÿ‡ธ USA
15.2 1,256.23%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.